News Center

Home page

Peak Report

News reports

Pharmaceutical Company Invests in Beihui Bio

Release time:

2020-08-14

Pharmaceutical Company Invests in Beihui Biology

Peak Pharmaceutical Plate to Expand Its Territory

News 2# September 28 , the 9th Board of Directors of the Group Company deliberated and passed the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing Chairman of the Board". On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation. Beihui Biology was formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through cooperation with Yale University, we have obtained patent authorization and commercial development license for the new anti-cancer chemical drug troxacitabine (

trokacitabine

)(the national clinical approval for the new drug has been obtained in 2016 8 ), the anti-hepatitis B chemical drug clevudine (Clevudine ). Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biological Holdings, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly established by the Chinese government and foreign governments in Guangxi. It covers an area of

214.46

mu and has basically completed production workshops with multiple dosage forms such as percolation, tincture, solid preparation and liquid preparation, it has now entered the GMP certification phase. Guanghui Pharmaceutical has 77 drug approvals mainly for proprietary Chinese medicine preparations. Its main products include Huoxiang Zhengqi Water, Shidishui, Chen Xianglu Bailu Tablets, Compound Pearl Jiedu Oral Liquid, Yigan Mingmu Oral Liquid, etc. Among them, Yigan Mingmu Oral Liquid and Pearl Jiedu Oral Liquid are exclusive products. According to the cooperation agreement, when the agreed preconditions are met, Jianfeng Pharmaceutical plans to increase the capital of Beihui Biology in four phases. After the agreement comes into effect, it will make the first phase of investment and will contribute

,000

yuan to increase the capital of Beihui Biology by ,000 shares (accounting for.20% of shares); the second phase invested yuan to increase shares of Beihui Biology, and at the same time invested yuan to accept shares of Beihui Biology. In the third and fourth phases, the capital increase was ,1400 shares respectively. The capital increase price was determined through negotiation based on the evaluation value of Beihui Biology at that time. If the capital increase and equity transfer are all completed, Peak Pharmaceuticals will hold 7500 shares of Beihui Bio (accounting for 50.68% of the equity, the calculation of the equity ratio does not take into account the introduction of other investors). The next few phases of investment will be implemented in stages according to the investment prerequisites agreed in the agreement, the progress of product development, the operation of the target company and other factors. This cooperation is based on the company's strategic policy of "cooperating and innovating to strengthen the main business, standardizing science and seeking development". It is the specific implementation of expanding and strengthening the pharmaceutical business, which will help to further enhance the new drug research and development capability of Jianfeng Pharmaceutical and further expand the scale of the company's pharmaceutical business. (Zhou Hengbin)

More information

2022 China's Top 100 Building Materials Enterprises 2022 China's Top 100 Cement Clinker Production Capacity Peak even on two authoritative lists

In March, the authoritative organization of the cement industry successively released two series of lists of China's top 500 building materials enterprises in 2022 and China's top 100 cement clinker production capacity in 2022. Jianfeng Group ranked among the "top 100" in the two lists ". The list of China's top 500 building materials enterprises was officially released in early March. This series of lists was selected by the China Building Materials Enterprise Management Association. Through more than 20 years of comprehensive data research on China's building materials industry, referring to international practices, the rankings are based on the company's annual operating income., Cement products, building ceramics, waterproof materials, aluminum-plastic profiles, coatings, glass, building materials equipment manufacturing and other sub-industries related to building materials. Jianfeng Group ranks 96th among the companies on the list and 27th among the cement manufacturers on the list. On March 16, the awarding ceremony of 2022 China's top 100 cement clinker production capacity list was held in Hangzhou. This series of lists is released by China Cement Network, an authoritative organization in China's cement industry. The ranking is based on the total production capacity (excluding the production capacity of other kiln types and grinding stations) of new dry clinker production lines completed and put into operation by Chinese cement enterprises in China as of December 31, 2022. The data statistics are calculated based on the design production capacity and 310 days of annual operation. Jianfeng Group ranked 53rd with an annual design capacity of 3.627 million tons. (this newspaper reporter)

2023

03-21

Company sends off retired employees

On the morning of February 22, the trade union of the group company held a simple and warm farewell party for retired employees in 2021-2022. More than 50 retired employees gathered together to discuss and exchange with Jiang Xiaomeng and other group leaders.

2023

03-04

On the first day of the new year, group leaders went to the grassroots level.

On January 29, the first day of work after the Spring Festival holiday, the leaders of the group company made a video connection to subordinate enterprises stationed abroad, and separately visited the gold enterprises to learn about the resumption of work and put forward requirements for the implementation of the work plan for the new year.

2023

02-17

Group Companies Commend 2022 Advanced

On the morning of January 18, the group company held the 2022 annual summary commendation meeting to review the work of the previous year, make arrangements for the work in 2023, sign the 2023 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2022 advanced collectives and individuals.

2023

01-29

Jiang Xiaomeng re-elected chairman of the Municipal Federation of Industry and Commerce

On December 24, 2022, the Jinhua Federation of Industry and Commerce (General Chamber of Commerce) held the seventh member representative meeting. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, was re-elected as the chairman of the Municipal Federation of Industry and Commerce at this meeting.

2023

01-12

Peak Pharmaceutical Donates Epidemic Prevention Materials

Since the optimization and adjustment of the new crown infection epidemic management policy, there has been an explosive growth of infected people in the country, and the pressure on the supply of related materials has increased sharply. Before and after New Year's Day, the company has twice organized epidemic prevention materials, through the Jinhua City Charity Federation, Jinhua City Economic and Technological Development Zone Charity Federation targeted donations, a total value of more than 200,000 yuan.

2023

01-12

< 1 2 3 4...61 > 跳转到页